Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05547542 · ClinicalTrials.gov registry record · Phase 1

Positron Emission Tomography (PET) Trial to Evaluate Target Occupancy of CVL-354 at Kappa and Mu Opioid Receptors in Brain Following Oral Dosing

A Phase 1 study, sponsored by Cerevel Therapeutics.

Completed
Registry status
Phase 1
Development phase
19
Enrollment target

NCT05547542: Completed Phase 1 study, sponsored by Cerevel Therapeutics.

NCT05547542 is a Phase 1 study that has completed, run by Cerevel Therapeutics. The registered enrollment target is 19 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05547542, a Phase 1 study, has completed, sponsored by Cerevel Therapeutics.

COMPLETED
Registry status
Phase 1
Development phase
19 participants
Enrollment target

Study Summary

The primary purpose of this study is to assess the target occupancy at kappa and mu opioid receptors in the brain after single oral doses of CVL-354 in healthy adult participants.

Interventions

  • DRUG CVL-354
  • DRUG [11C]-LY2795050
  • DRUG [11C]-carfentanil

Trial Details

FieldValue
Enrollment Target 19 participants
Start Date 2023-03-02
Est. Completion 2024-08-06
Phase Phase 1
Cerevel Therapeutics

21 total trials

What the finished NCT05547542 record still lists

NCT05547542 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (68% lower).

The record links to 0 conditions, and to 3 interventions - of which CVL-354 is the first listed.

NCT05547542 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05547542 about?

NCT05547542 is a clinical study titled "Positron Emission Tomography (PET) Trial to Evaluate Target Occupancy of CVL-354 at Kappa and Mu Opioid Receptors in Brain Following Oral Dosing". The primary purpose of this study is to assess the target occupancy at kappa and mu opioid receptors in the brain after single oral doses of CVL-354 in healthy adult participants.

What is the current status of trial NCT05547542?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2023-03-02. Estimated completion is 2024-08-06.

What interventions are being tested in trial NCT05547542?

The interventions under investigation include: CVL-354 (DRUG), [11C]-LY2795050 (DRUG), [11C]-carfentanil (DRUG).

Who is sponsoring clinical trial NCT05547542?

This trial is sponsored by Cerevel Therapeutics, which has 21 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05547542's enrollment target sits among peer trials

19 1716th of 2000 higher than 281 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03207464 · 19 participants · Phase 1

    Molecular Imaging of NET Using [C-11]MRB-PET in MS

  • NCT04318717 · 19 participants · Phase 2

    Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma

  • NCT05103904 · 19 participants · Phase 2

    Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant

  • NCT05607407 · 19 participants · Phase 2

    Methimazole in Patients With Progressive Glioblastoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05547542, the US trial registry maintained by the National Library of Medicine. NCT05547542 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.